Blood pressure stability in hemodialysis patients confers a survival advantage: results from a large retrospective cohort study

Jochen G Raimann^1,2,4, Len A Usvyat^1,4, Stephan Thijssen^1,2, Peter Kotanko^1,2, John Rogus³, Eduardo Lacson Jr³ and Nathan W Levin^1,2

1. ¹Renal Research Institute, New York, New York, USA
2. ²Beth Israel Medical Center, New York, New York, USA
3. ³Fresenius Medical Care NA, Waltham, Massachusetts, USA

Abstract

The association between changes in systolic and diastolic blood pressure, and the use of cardioprotective drugs on survival of incident hemodialysis patients, was examined in this retrospective cohort study. Pre-hemodialysis systolic and diastolic blood pressures were averaged over the first month of hemodialysis. 

Slopes, reflecting temporal changes, were computed by linear regression of systolic blood pressures and Cox regression was used for survival analyses. Patients were initially stratified into four cohorts (below 120, 120 to 150, 151 to 180, and above 180 mm Hg) and further subdivided into groups with stable (no more than a 1-mm Hg change per month), increasing (over 1-mm Hg per month), and decreasing (less than 1-mm Hg per month) slopes during the first year. 

Analyses were repeated for patients who were treated with cardioprotective drugs for 1 month or more in the second year. In 10,245 patients (59% prescribed cardioprotective drugs), both increases and decreases in all ranges of blood pressure were associated with worse outcomes, whereas stable blood pressure had a survival advantage at all levels of systolic and diastolic pressures.

Use of cardioprotective drugs attenuated changes and improved survival. Validation and sensitivity analyses confirmed the primary findings. Therefore, previous temporal trends need to be considered in patient care, and the use of cardioprotective agents is associated with enhanced survival at all blood pressure levels.

Read full text here